Hepatology · Rare DiseaseTrial Updateclinicalmid-term

Ipsen initiates trial for elafibranor in Primary Sclerosing Cholangitis

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Ipsen3 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/3/2026, 6:02:43 AM

Assessment confidence: 87% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of Ipsen's trial for elafibranor in Primary Sclerosing Cholangitis represents a significant step in addressing an unmet medical need in a rare disease area. Successful trial outcomes could enhance Ipsen's position in hepatology and disrupt the competitive landscape among companies focused on liver diseases. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (8 high-relevance).

Strategic Assessment

Successful outcomes could enhance Ipsen's portfolio in hepatology and provide a new treatment option for PSC, influencing market dynamics. The strongest clinical anchor is A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis (ClinicalTrials.gov), sub-indication match (rare disease); entity match (ipsen). In rare disease, 7 regulatory and 0 competitive items passed relevance filtering for Ipsen.

Competitive Pressure

The most relevant competitive pressure comes from This trial positions Ipsen in the rare disease space, potentially addressing an unmet need in PSC treatment, which may impact competitors focusing on liver diseases..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda). The trial's outcomes will be critical for regulatory approval, influencing the labeling and market entry of elafibranor as a treatment for PSC.

Key Risks

Elevated medium regulatory exposure for Ipsen could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, elafibranor could capture market share in the PSC treatment space, potentially leading to increased revenues for Ipsen and altering competitive dynamics.
Successful outcomes could enhance Ipsen's portfolio in hepatology and provide a new treatment option for PSC, influencing market dynamics.

What Would Change This Assessment

This becomes more urgent if Monitor trial progress, patient recruitment rates, and interim results over the next five years.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Sub-indication match (rare disease)
FDA document
View source

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
ClinicalTrials.govhigh relevance
Sub-indication match (rare disease); Entity match (ipsen)
FDA document
View source
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
ClinicalTrials.govmedium relevance
Sub-indication match (rare disease)
FDA document
View source
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
EVERO Drug-coated Balloon (DCB) Randomized Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Use of Custom-Made Acrylic Palatal Stent to Minimize Donor Site Morbidity After Suture-Free Epithelialized Gingival Graft Harvesting: A Randomized Clinical Trial
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Microneedle Delivery of Amphotericin B Shows Promise for American Cutaneous Leishmaniasis Treatment
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

The Effect of Moxibustion at the Dazhui Point on Hypothermia and Maternal Comfort During Cesarean Delivery: A Randomized Controlled Trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Oral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ipsen
liver disease competitors

Commercial impact

medium

If successful, elafibranor could capture market share in the PSC treatment space, potentially leading to increased revenues for Ipsen and altering competitive dynamics.

Regulatory impact

medium

The trial's outcomes will be critical for regulatory approval, influencing the labeling and market entry of elafibranor as a treatment for PSC.

What to watch

Monitor trial progress, patient recruitment rates, and interim results over the next five years.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.